Efficacy of Solifenacin in Children with Idiopathic Overactive Bladder

HE Ping; ZHANG Ye; ZHANG Yin; SUN Qihang; YOU Long; CHAO Min

doi:10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.20240424.003

您当前的位置：

首页 >

文章列表页 >

Efficacy of Solifenacin in Children with Idiopathic Overactive Bladder

Topic on overactive bladder in children | 更新时间：2024-06-05

- Efficacy of Solifenacin in Children with Idiopathic Overactive Bladder
- Journal of Sun Yat-sen University(Medical Sciences) Vol. 45, Issue 3, Pages: 337-343(2024)
- 作者机构：
  
  1.安徽医科大学附属省儿童医院泌尿外科，安徽合肥 230051
  2.安徽医科大学第五临床医学院泌尿外科，安徽合肥 230051
- 作者简介：
  
  CHAO Min； E-mail： cm0654@sina.com
- 基金信息：
- DOI：10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.20240424.003
  CLC： R726.9
- Published：20 May 2024，
  
  Received：20 February 2024，
  
  Accepted：23 April 2024
扫描看全文
何萍,张晔,张殷等.索利那新治疗儿童特发性膀胱过度活动症的疗效分析[J].中山大学学报（医学科学版）,2024,45(03):337-343.

HE Ping,ZHANG Ye,ZHANG Yin,et al.Efficacy of Solifenacin in Children with Idiopathic Overactive Bladder[J].Journal of Sun Yat-sen University(Medical Sciences),2024,45(03):337-343.
何萍,张晔,张殷等.索利那新治疗儿童特发性膀胱过度活动症的疗效分析[J].中山大学学报（医学科学版）,2024,45(03):337-343. DOI： 10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.20240424.003.

HE Ping,ZHANG Ye,ZHANG Yin,et al.Efficacy of Solifenacin in Children with Idiopathic Overactive Bladder[J].Journal of Sun Yat-sen University(Medical Sciences),2024,45(03):337-343. DOI： 10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.20240424.003.

摘要

目的

探讨索利那新改善儿童特发性膀胱过度活动症症状的疗效分析。

方法

收集2022年3月至2023年3月于我院泌尿外科门诊就诊的67例特发性膀胱过度活动症患儿的临床资料，所有患儿均经过至少2周行为治疗症状无明显改善，其中52例予索利那新（每天5 mg）口服（服药组），并根据患儿是否伴有尿失禁症状分为干性组（27例）与湿性组（25例），剩余15例拒绝服药的患儿继续维持行为治疗（观察组）。自服药开始随访3个月，分别收集每名患儿服药前、服药2周、服药4周、服药8周、服药12周连续3 d排尿日记及膀胱过度活动症症状评分表（OABSS），并记录病程中患儿不良反应情况。

结果

67例患儿均完成随访，其中44例患儿治愈（观察组3人治愈，12人未治愈；服药组41人治愈，11人未治愈），4例出现不良反应。①服药组较观察组随访末期OABSS评分显著降低（

=4.524，

0.001）；观察组与服药组的治愈率分别20%、78.8%，存在显著差异（

=15.367，

0.001）；②随随访时间延长，服药组患儿平均每次排尿量增加（

=9.707，

0.001）、日平均排尿次数降低（

=3.837，

=0.009）、尿急评分（

=482.835，

0.001）下降；③干性组与湿性组随访3个月治愈率分别为81.5%、76%，差异无统计学意义（

=0.234，

=0.629）。

结论

特发性膀胱过度活动症患儿口服索利那新（每日5 mg）可显著减少日平均排尿次数，增加平均每次排尿量，缓解尿急症状，不良反应较少。但是对于治愈湿性患儿尿失禁症状疗效不显著。

Abstract

Objective

To explore the efficacy of Solifenacin in the treatment of children with idiopathic overactive bladder （OAB）.

Methods

The study included 67 children with idiopathic OAB treated in the urology clinic of our hospital from March 2022 to March 2023. After at least 2-week-long behavioral therapy showed no significant therapeutic effect， 52 of the cases in the trial group were given oral Solifenacin 5 mg once daily and the other 15 cases in the control group continued the behavioral therapy. The cases in trial group were subdivided into OAB-dry group （27 cases without urinary incontinence） and OAB-wet group （25 cases with urinary incontinence）. The 3-day micturition diary， OAB Symptom Scores （OABSS） and the adverse reactions were recorded and analyzed before， at Weeks 2， 4， 8 and 12 after the treatment.

Results

Of all the 67 cases who completed a 3-month follow-up， 44 were cured including 41 in the trial group and 3 in the control group， 4 presented with adverse reactions. After the 3-month follow-up， the OABSS declined markedly in trial group than in control group （

=4.524，

0.001）； the cure rates in trial group and control group are 78.8% and 20% respectively， with significant difference （

=15.367，

0.001）. At each follow-up，we found increased mean voided volume （

=9.707，

0.001）， reduced mean voiding frequency during daytime （

=3.837，

=0.009） and decreased voiding urgency （

=482.835，

0.001）. After the 3-month follow-up， the cure rates in OAB-dry group and OAB-wet group are 81.5% and 76% respectively， with no significant difference （

=0.234，

=0.629）.

Conclusions

In children with idiopathic OAB， oral Solifenacin 5 mg once daily could significantly increase mean voided volume， reduce mean voiding frequency during daytime， relieve symptoms of urinary urgency and lead to fewer adverse reactions， but is not significantly effective for the treatment of urinary incontinence in OAB-wet children .

关键词

膀胱过度活动症尿失禁尿急儿童索利那新

Keywords

overactive bladder （OAB）urinary incontinenceurinary urgencychildrenSolifenacin

references

Sultan AH， Monga A， Lee J， et al. An International Urogynecological Association （IUGA）/International Continence Society （ICS） joint report on the terminology for female anorectal dysfunction［J］. Neurourol Urodyn， 2017， 36（1）： 10-34.

中华医学会小儿外科学分会小儿尿动力和盆底学组，中华医学会小儿外科学分会泌尿外科学组.儿童膀胱过度活动症诊断和治疗中国专家共识［J］. 中华医学杂志，2021， 101（40）： 3278-3286.

Pediatric Urology and Pelvicum Group of the Pediatric Surgery Branch of the Chinese Medical Association， Urology Group of the Pediatric Surgery Branch of the Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of bladder hyperactivity in children［J］. Natl Med J China， 2021， 101 （40）： 3278-3286.

Austin PF， Bauer SB， Bower W， et al. The standardization of terminology of lower urinary tract function in children and adolescents： update report from the standardization committee of the International Children′s Continence Society［J］. Neurourol Urodyn， 2016， 35（4）： 471‐481.

Lightner DJ， Gomelsky A， Souter L， et al. Diagnosis and treatment of overactive bladder （non‐neurogenic） in adults：AUA/SUFU Guideline Amendment 2019［J］. J Urol， 2019， 202（3）： 558‐563.

Ramsay S， Naud É， Simonyan D， et al. A randomized， crossover trial comparing the efficacy and safety of fesoterodine and extended-release oxybutynin in children with overactive bladder with 12-month extension on fesoterodine： the FOXY study［J］. Can Urol Assoc J， 2020， 14（6）： 192-198.

邓永继，马耿，郭云飞，等. 托特罗定和奥昔布宁治疗原发性儿童膀胱过度活动症的疗效和安全性比较［J］. 中国当代儿科杂志， 2011， 13（1）： 26‐28.

Deng YJ， Ma G， Guo YF， et al. Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder［J］. Chin J Contemp Pediatr， 2011， 13（1）： 26-28.

刘秉乾，李沛寰，李建华，等. 索利那新与托特罗定治疗膀胱过度活动症效果及安全性的荟萃分析［J］. 中华医学杂志， 2014， 94（30）： 2350‐2354.

Liu BQ， Li PH， Li JH， et al. Meta-analysis of the effect and safety of Solinaxin and totrodine in the treatment of bladder hyperactivity［J］. Natl Med J Chin， 2014， 94（30）： 2350‐2354.

Soliman MG， El-Abd S， El-Gamal OM， et al. Mirabegron versus solifenacin in children with overactive bladder： prospective randomized single-blind controlled trial［J］. Urol Int， 2021， 105（11-12）： 1011-1017.

张晔，张殷，潮敏，等. 小剂量索利那新治疗儿童特发性膀胱过度活动症的短期疗效与安全性分析［J］. 临床小儿外科杂志， 2023， 22（2）： 134-138.

Zhang Y， Zhang Y， Chao M， et al. Short-term efficacy and safety of low-dose solinacin for newly diagnosed idiopathic overactive bladder in children［J］. J Clin Pediat Surg， 2023， 22（2）： 134-138.

毛秋方. 豫北地区儿童下尿路症状的发生率和危险因素及其对心理的影响［D］. 新乡医学院， 2022.

Mao QF. Incidengce and risk factors of lower urinary tract symptoms in children in northern Henan and their impact on psychology［D］. Xinxiang Medical University， 2022.

Newgreen D， Bosman B， Hollestein-Havelaar A， et al. Solifenacin in children and adolescents with overactive bladder： results of a phase 3 randomised clinical trial［J］. Eur Urol， 2017， 71（3）： 483-490.

Drake MJ， Chapple C， Esen AA， et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to Initial 4-week solifenacin monotherapy： a randomised double-blind multicentre phase 3B study （BESIDE）［J］. Eur Urol， 2016， 70（1）： 136-145.

Liu B， Liu Y， Qin Z， et al. Electroacupuncture versus pelvic floor muscle training plus solifenacin for women with mixed urinary incontinence： a randomized noninferiority trial［J］. 2019， 94（1）： 54-65.

高振涛，周祥福，陈雪莲，等. 点阵CO2激光治疗女性轻中度压力性尿失禁的临床疗效分析［J］. 中华腔镜泌尿外科杂志（电子版）， 2022， 16（1）： 40-44.

Gao ZT， Zhou XF， Chen XL， et al. Clinical efficacy analysis of fractional CO2 laser in the treatment of female with mild-to-moderate stress urinary incontinence［J］. Chin J Endourol （Elec Edi）， 2022， 16（1）： 40-44.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical and Genetic Study on 48 Children with Short Stature of Unknown Etiology

Nutritional Status of Children Aged 3 to 7 Years in Zhag′yab， Tibet

The Exploration of Glymphatic System Alteration in Pediatric Acute Lymphoblastic Leukemia Using DTI-ALPS Method

The Brain Structure Volume Estimation Based on Synthetic MRI in Pediatric Acute Lymphoblastic Leukemia

Related Author

ZHANG Ye

ZHANG Yin

SUN Qi-hang

YOU long

HOU Lele

LIN Shaofen

LI Xiaojuan

LIU Zulin

Related Institution

Children’s Medical Center， Sun Yat-sen Memorial Hospital， Sun Yat-sen University

Cellular and Molecular Diagnostics Center， Sun Yat-sen Memorial Hospital， Sun Yat-sen University

Department of Pediatrics，The Third Affiliated Hospital of Sun Yat-sen University

Department of Maternal and Child Health， People's Hospital of Zhag′yab County， Zhag′yab

Department of Internal Medicine and Pediatrics， People's Hospital of Zhag′yab County， Zhag′yab

Postal code：510080
Tel：020-87331643，87330827 Email：xbmed@mail.sysu.edu.cn
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰